奇正藏药(002287) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥519,212,989.60, representing a year-on-year increase of 28.89%[5] - Net profit attributable to shareholders for the same period was ¥127,221,135.64, a significant increase of 137.34% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥126,907,331.26, up by 63.37% year-on-year[5] - Basic earnings per share for Q3 2022 were ¥0.2407, an increase of 137.24% compared to the same period last year[5] - Net profit for the current period was ¥357,525,838.41, a decrease from ¥645,927,284.24, reflecting a decline of approximately 44.5%[29] - Basic earnings per share were CNY 0.6784, down from CNY 1.2247 in the previous period[32] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,457,758,867.56, a decrease of 1.98% from the end of the previous year[5] - The total assets decreased to ¥5,457,758,867.56 from ¥5,567,753,848.57, a reduction of about 2%[25] - Current liabilities totaled ¥1,084,226,284.39, down from ¥1,307,979,313.93, showing a decrease of approximately 17%[25] - Non-current liabilities increased to ¥1,105,008,433.53 from ¥1,039,391,910.81, marking an increase of about 6.3%[25] - The total equity attributable to shareholders of the parent company increased to ¥3,216,024,928.04 from ¥3,169,030,586.36, showing a growth of approximately 1.5%[25] Cash Flow - The company's cash flow from operating activities showed a significant decline, with a net amount of ¥192,374,939.97, down by 66.32% year-on-year[5] - Net cash flow from operating activities decreased by 66.32% to $192.37 million, primarily due to reduced cash received from sales and increased cash payments for employee compensation[14] - Cash inflow from operating activities totaled CNY 1,351,313,488.40, a decrease of 236,727,728.06 from CNY 1,588,041,216.46 in the previous period[33] - Net cash flow from operating activities was CNY 192,374,939.97, significantly lower than CNY 571,227,074.26 in the previous period[35] - Cash outflow from investing activities was CNY 1,397,190,085.90, compared to CNY 2,752,828,076.34 in the previous period[35] - Net cash flow from investing activities improved by 80.99% to -$279.09 million, as cash used for purchasing wealth management products decreased[14] - Cash flow from financing activities resulted in a net outflow of -CNY 399,891,357.86, compared to -CNY 207,157,680.76 in the previous period[35] Investment and Expenses - The company recognized an investment loss of ¥75,006,700.00 from its participation in a merger fund during the reporting period[9] - The financial expenses increased by 171.03% to ¥30,399,841.09 due to reduced interest income and increased loan interest[11] - The company's investment income decreased by 120.85% to -$60.75 million due to reduced long-term equity investment returns and wealth management product investment income[14] - The company reported a significant decline in investment income, with a loss of ¥60,752,497.46 compared to a gain of ¥291,417,294.11 in the previous period[29] - Research and development expenses for the current period were ¥46,893,261.76, compared to ¥44,393,885.66 in the previous period, reflecting an increase of approximately 5.6%[26] Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,144, with the largest shareholder holding 68.75% of the shares[15] - Minority interests loss increased by 37.97% to -$2.02 million, indicating higher losses from controlled subsidiaries[14] Other Financial Metrics - The weighted average return on equity was 4.40%, reflecting a decrease of 13.85% year-on-year[5] - The company reported a loss of ¥40,062.14 from the disposal of non-current assets during the reporting period[6] - Total operating revenue for the current period reached ¥1,416,132,351.38, an increase from ¥1,189,266,190.30 in the previous period, representing a growth of approximately 19.1%[26] - Total operating costs amounted to ¥1,004,641,422.30, up from ¥844,453,879.84, indicating a rise of about 18.9%[26] - Total comprehensive income for the period amounted to CNY 361,177,638.72, a decrease of 645,729,862.64 compared to the previous period[32] - The company's cash and cash equivalents decreased significantly, impacting liquidity and operational flexibility[25] - The ending balance of cash and cash equivalents was CNY 183,676,142.50, down from CNY 726,006,732.94 in the previous period[35] Audit Information - The company did not undergo an audit for the third quarter report[37]